Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial

[1]  R. Steinbrook.  Medicare and erythropoietin. , 2007, The New England journal of medicine.

[2]  G. Remuzzi,et al.  Correction of anemia--payoffs and problems. , 2006, The New England journal of medicine.

[3]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[4]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[5]  A. Bolger,et al.  Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. , 2006, Journal of the American College of Cardiology.

[6]  S. Solomon,et al.  Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF)™ Trial , 2006 .

[7]  D. J. Veldhuisen,et al.  Safety and efficacy of darbepoetin alfa treatment in anemic patients with symptomatic heart failure: a pooled analysis of two randomized, double-blind, placebo-controlled trials , 2006 .

[8]  P. Armstrong,et al.  549 Randomized, double-blind, placebo-controlled trial to assess the impact of darbepoetin alfa treatment on exercise tolerance in anemic patients with symptomatic heart failure: results from STAMINA-HeFT , 2006 .

[9]  S. Katz,et al.  Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options , 2006, Circulation.

[10]  P. Ponikowski,et al.  Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia , 2006 .

[11]  S. Solomon,et al.  Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program , 2006, Circulation.

[12]  J. Cleland,et al.  Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT‐BPLA , 2005, European journal of heart failure.

[13]  S. Solomon,et al.  Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. , 2005, American heart journal.

[14]  A. Voors,et al.  Erythropoietin in cardiovascular diseases. , 2004, European heart journal.

[15]  D. Silverberg,et al.  The importance of anemia and its correction in the management of severe congestive heart failure , 2002, European journal of heart failure.

[16]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[17]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[18]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.